Treatment of Gonadotropin-Dependent precocious puberty

Research output: Contribution to journalArticle

Abstract

Gonadotropin dependant precocious puberty is a heterogeneous disease with variable clinical presentations ranging from incomplete forms of precocious pubertal development to rapidly progressive forms. Although there is some controversy about the indications for treatment of central precocious puberty, in this chapter we review and clarify the indications as well as summarize the various methods available for monitoring therapy. Gonadotropin releasing hormone agonists (GnRHa) are currently considered the treatment of choice for central precocious puberty (CPP). Long-term outcome studies have shown that GnRHa have completely reversible suppressive effects on the hypothalamic-pituitary-gonadal axis, preserve final adult height, and have no long-term effects on bone mineral density and body composition in children with CPP. Newer therapies for use in CPP such as GnRH antagonists and third generation aromatase inhibitors are currently being studied and may be additional treatment options in the future.

Original languageEnglish
Pages (from-to)345-362
Number of pages18
JournalCurrent Clinical Neurology
StatePublished - 2010
Externally publishedYes

Fingerprint

Precocious Puberty
Gonadotropins
Gonadotropin-Releasing Hormone
Therapeutics
Aromatase Inhibitors
Body Composition
Bone Density
Outcome Assessment (Health Care)
Central Precocious Puberty

Keywords

  • Bone density
  • Final height
  • GnRH agonists
  • Gonadotropin-dependent precocious puberty
  • Growth hormone
  • Oxandrolone
  • Skeletal maturation

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Treatment of Gonadotropin-Dependent precocious puberty. / Nabhan, Zeina; Walvoord, Emily.

In: Current Clinical Neurology, 2010, p. 345-362.

Research output: Contribution to journalArticle

@article{75a6829628bc40d7b4624ea35b0065da,
title = "Treatment of Gonadotropin-Dependent precocious puberty",
abstract = "Gonadotropin dependant precocious puberty is a heterogeneous disease with variable clinical presentations ranging from incomplete forms of precocious pubertal development to rapidly progressive forms. Although there is some controversy about the indications for treatment of central precocious puberty, in this chapter we review and clarify the indications as well as summarize the various methods available for monitoring therapy. Gonadotropin releasing hormone agonists (GnRHa) are currently considered the treatment of choice for central precocious puberty (CPP). Long-term outcome studies have shown that GnRHa have completely reversible suppressive effects on the hypothalamic-pituitary-gonadal axis, preserve final adult height, and have no long-term effects on bone mineral density and body composition in children with CPP. Newer therapies for use in CPP such as GnRH antagonists and third generation aromatase inhibitors are currently being studied and may be additional treatment options in the future.",
keywords = "Bone density, Final height, GnRH agonists, Gonadotropin-dependent precocious puberty, Growth hormone, Oxandrolone, Skeletal maturation",
author = "Zeina Nabhan and Emily Walvoord",
year = "2010",
language = "English",
pages = "345--362",
journal = "Current Clinical Neurology",
issn = "1559-0585",
publisher = "Springer Science + Business Media",

}

TY - JOUR

T1 - Treatment of Gonadotropin-Dependent precocious puberty

AU - Nabhan, Zeina

AU - Walvoord, Emily

PY - 2010

Y1 - 2010

N2 - Gonadotropin dependant precocious puberty is a heterogeneous disease with variable clinical presentations ranging from incomplete forms of precocious pubertal development to rapidly progressive forms. Although there is some controversy about the indications for treatment of central precocious puberty, in this chapter we review and clarify the indications as well as summarize the various methods available for monitoring therapy. Gonadotropin releasing hormone agonists (GnRHa) are currently considered the treatment of choice for central precocious puberty (CPP). Long-term outcome studies have shown that GnRHa have completely reversible suppressive effects on the hypothalamic-pituitary-gonadal axis, preserve final adult height, and have no long-term effects on bone mineral density and body composition in children with CPP. Newer therapies for use in CPP such as GnRH antagonists and third generation aromatase inhibitors are currently being studied and may be additional treatment options in the future.

AB - Gonadotropin dependant precocious puberty is a heterogeneous disease with variable clinical presentations ranging from incomplete forms of precocious pubertal development to rapidly progressive forms. Although there is some controversy about the indications for treatment of central precocious puberty, in this chapter we review and clarify the indications as well as summarize the various methods available for monitoring therapy. Gonadotropin releasing hormone agonists (GnRHa) are currently considered the treatment of choice for central precocious puberty (CPP). Long-term outcome studies have shown that GnRHa have completely reversible suppressive effects on the hypothalamic-pituitary-gonadal axis, preserve final adult height, and have no long-term effects on bone mineral density and body composition in children with CPP. Newer therapies for use in CPP such as GnRH antagonists and third generation aromatase inhibitors are currently being studied and may be additional treatment options in the future.

KW - Bone density

KW - Final height

KW - GnRH agonists

KW - Gonadotropin-dependent precocious puberty

KW - Growth hormone

KW - Oxandrolone

KW - Skeletal maturation

UR - http://www.scopus.com/inward/record.url?scp=79953654671&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953654671&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:79953654671

SP - 345

EP - 362

JO - Current Clinical Neurology

JF - Current Clinical Neurology

SN - 1559-0585

ER -